Durvalumab as third-line or later treatment for advanced ...

There is an unmet need for treatment options in this disease area 3.1 Locally advanced unresectable non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease with complex symptoms. Durvalumab is indicated for use in people whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed after ................
................